Lessons learned from a highly-active CD22-specific chimeric antigen receptor

CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Adrienne H., Haso, Waleed M., Orentas, Rimas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586/
https://www.ncbi.nlm.nih.gov/pubmed/23734316
http://dx.doi.org/10.4161/onci.23621
_version_ 1782269585638031360
author Long, Adrienne H.
Haso, Waleed M.
Orentas, Rimas J.
author_facet Long, Adrienne H.
Haso, Waleed M.
Orentas, Rimas J.
author_sort Long, Adrienne H.
collection PubMed
description CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the development of such a highly-active CAR was its ability to target a membrane-proximal epitope of CD22.
format Online
Article
Text
id pubmed-3654586
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545862013-06-03 Lessons learned from a highly-active CD22-specific chimeric antigen receptor Long, Adrienne H. Haso, Waleed M. Orentas, Rimas J. Oncoimmunology Author's View CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the development of such a highly-active CAR was its ability to target a membrane-proximal epitope of CD22. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654586/ /pubmed/23734316 http://dx.doi.org/10.4161/onci.23621 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Long, Adrienne H.
Haso, Waleed M.
Orentas, Rimas J.
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title_full Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title_fullStr Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title_full_unstemmed Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title_short Lessons learned from a highly-active CD22-specific chimeric antigen receptor
title_sort lessons learned from a highly-active cd22-specific chimeric antigen receptor
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586/
https://www.ncbi.nlm.nih.gov/pubmed/23734316
http://dx.doi.org/10.4161/onci.23621
work_keys_str_mv AT longadrienneh lessonslearnedfromahighlyactivecd22specificchimericantigenreceptor
AT hasowaleedm lessonslearnedfromahighlyactivecd22specificchimericantigenreceptor
AT orentasrimasj lessonslearnedfromahighlyactivecd22specificchimericantigenreceptor

Ejemplares similares